XSTO
EXPRS2
Market cap271kUSD
Oct 09, Last price
1.09SEK
1D
2.83%
1Q
-24.31%
Jan 2017
-84.87%
IPO
-83.90%
Name
ExpreS2ion Biotech Holding AB
Chart & performance
P/E
—
P/S
0.76
EPS
—
Div yield, %
—
Shrs. gr., 5y
42.85%
Rev. gr., 5y
-7.01%
Revenues
4m
+21.37%
Net income
-38m
L+5.68%
CFO
-41m
L+20.56%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.
Key people
Martin Roland Jensen
Chairman of the Board
Bent U. Frandsen
Chief Executive Officer · since 2019
Charlotte Dyring
Chief Operating Officer · since 2016
Willem Adriaan de Jongh
Chief Scientific Officer
Director · since 2017
Gitte Pedersen
Director
Allan Rosetzsky
Director
Headquarters & legal address
C/O Mindpark
Rönnowsgatan 8c
Helsingborg, M 252 25
SE
Rönnowsgatan 8c
Helsingborg, M 252 25
SE
Address
C/O Mindpark
Ronnowsgatan 8c
Helsingborg, M 252 25
SE
Ronnowsgatan 8c
Helsingborg, M 252 25
SE
Previous name
StartVision 3223 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||